Keith Stockerl-Goldstein, MD 😷

Washington U. School of Medicine.
Assoc Director Hem/Onc Fellowship.
Myeloma, Amyloidosis, Leukemia, Lymphoma & BMT physician and researcher.
Tweets are my own.

[Keith Stockerl-Goldstein, MD 😷 @CyclingDoctor]

Whenever I have a tough day at work I take a look at this homework assignment from the granddaughter of one of my patients with 'motable bylomea'
#mmsm #bmtsm #MedTwitter

[Keith Stockerl-Goldstein, MD 😷 @CyclingDoctor]

https://t.co/SiEgW5Shv5

[Keith Stockerl-Goldstein, MD 😷 @CyclingDoctor]

Maltese Cross formations in a nerve biopsy-Congo red stain with polarized light (second is CR without polarized).
#amyloidosis #mmsm
@mtmdphd @RahulBanerjeeMD @vsanchorawala @Amyloid_Planet

[Keith Stockerl-Goldstein, MD 😷 @CyclingDoctor]

#mmsm

[awechalekar @awechalekar]

new era for AL Amyloidosis - efficacy of anti-fibril strategy - Anselamimab shows highly clinically meaningful improvement in survival and cardiovascular hospitalisation in prespecified patient subgroup ⁦@Amyloidosis_ARC⁩ ⁦@ISA_Amyloidosis⁩
https://t.co/pn4wtItA8F

[Keith Stockerl-Goldstein, MD 😷 @CyclingDoctor]

Disappointing. Hope to see data soon--maybe at #ASH25?
#mmsm

[Vaishali Sanchorawala @vsanchorawala]

The Phase III CARES trial of #anselamimab in #ALAmyloidosis did not meet its primary endpoint, but showed clinically meaningful benefit in a predefined high-risk subgroup.
More details to follow at upcoming meetings. @BU_Amyloidosis

https://t.co/UuGi30tsdi

[Mike Thompson, MD, PhD, FASCO @mtmdphd]

Myeloma / Plasma Cell Dyscrasia *DRAFT*~ #ASCO25Top10 (or so) #mmsm #mmMRD #ASCO25 - @mtmdphd - Update: 5/31/25 - cc @grpetersen1 - @HadidiSamer @AuclairDan @RahulBanerjeeMD @myelomaMD @bdermanmd @szusmani @CyclingDoctor @MyelomaTeacher

[Keith Stockerl-Goldstein, MD 😷 @CyclingDoctor]

#Caturday
Lorelai does not want the day to start.
@thechrisbarron

[Keith Stockerl-Goldstein, MD 😷 @CyclingDoctor]

I have a patient relocating to the Baton Rouge, LA area.
Any recommendations for an amyloid hematologist/oncologist?
#mmsm #amyloid #amyloidosis

[Keith Stockerl-Goldstein, MD 😷 @CyclingDoctor]

This graph says it all
#MedicalResearch #mmsm #leusm #mdssm #lymsm

[Keith Stockerl-Goldstein, MD 😷 @CyclingDoctor]

#bcsm #MedEd

[WashU Medicine Hematology-Oncology Fellowship @WashUHemOncFell]

Congratulations to one our outstanding @WashUHemOncFell Emily Podany @podanymd on the publication of her article "Racial Differences in ctDNA Profiles, Targeted Therapy Use, and Outcomes in Metastatic Breast Cancer" in @JAMANetworkOpen
@WashUOncology

https://t.co/0hooLKp1BY

[Keith Stockerl-Goldstein, MD 😷 @CyclingDoctor]

Court Pause on Cuts to Medical Research Funds Is Expanded Nationwide
https://t.co/KcL9SXbfeR

[Keith Stockerl-Goldstein, MD 😷 @CyclingDoctor]

Not sure they can cut the indirect rate on grants that are already funded without the approval of Congress.

[NIH @NIH]

Last year, $9B of the $35B that the National Institutes of Health (NIH) granted for research was used for administrative overhead, what is known as “indirect costs.” Today, NIH lowered the maximum indirect cost rate research institutions can charge the government to 15%, above what many major foundations allow and much lower than the 60%+ that some institutions charge the government today. This change will save more than $4B a year effective immediately.

[Keith Stockerl-Goldstein, MD 😷 @CyclingDoctor]

"There is a cult of ignorance in the United States, and there has always been. The strain of anti-intellectualism has been a constant thread winding its way through our political and cultural life, nurtured by the false notion that democracy means that 'my ignorance is just as good as your knowledge.'

-Isaac Asimov

[WashU Medicine Division of Oncology @WashUOncology]

Our @WashUOncology NCI SPORE program in leukemia received a 5-year $10.8 million grant to continue research into leukemia and other blood cancers!
@SitemanCenter @BarnesJewish @WashUDeptMed @washumedicine @WashUdbbs @WashUDPS

Read more:
https://t.co/CkmRTApvVa

[Keith Stockerl-Goldstein, MD 😷 @CyclingDoctor]

#Caturday
@thechrisbarron

[Keith Stockerl-Goldstein, MD 😷 @CyclingDoctor]

For the first time in its more than 60-year history, the CDC's Morbidity and Mortality Weekly Report (MMWR) did not go out as scheduled because of a communications pause at federal health agencies
https://t.co/3121gHJe2f

[WashU Medicine Hematology-Oncology Fellowship @WashUHemOncFell]

We are excited to welcome our 2025 @WashUHemOncFell Fellowship Class!
More details➡ https://t.co/proTHv9Sf4

@WashUDeptMed @SitemanCenter @BarnesJewish @washumedicine @SanaSaifUrRehm @NehaMehtaShahMD @CyclingDoctor @WashUHematology @WashUOncology @mpndoc @abbyWUim
#MedEd

[Jennifer Foltz, PhD @FoltzPhd]

The Foltz lab is growing! If you are interested in working on improving NK cell therapies for cancer, consider applying at: https://t.co/DjQaib0nz8 or reaching out to us at https://t.co/uaV443PUQA! @WashUDeptMed @WUSTLImmuno @SitemanCenter

[Keith Stockerl-Goldstein, MD 😷 @CyclingDoctor]

#MedEd @SitemanCenter @BarnesJewish @WashUMedFWIM @washumedicine
@abbyWUim

[Siteman Cancer Center @SitemanCenter]

We’re excited to welcome patients to our new, state-of-the-art building for comprehensive outpatient cancer care, where patients can see a multidisciplinary team of @washumedicine physicians in a supportive and calming environment.

https://t.co/mgZK1EBhzt

@HEC_TV
@BJC_HealthCare